Dual GIP/GLP-1 receptor agonist developed by Eli Lilly, approved for type 2 diabetes (Mounjaro®) and chronic weight management (Zepbound®).
Peptigrity tracks Tirzepatide across 219 shops with 575 independent lab tests and an average HPLC purity of 99.57%.
Dual GIP/GLP-1 receptor agonist developed by Eli Lilly, approved for type 2 diabetes (Mounjaro®) and chronic weight management (Zepbound®).
Every submitted test helps the community verify purity across brands. Free, fast, independent.